Key points are not available for this paper at this time.
Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.
Shepherd et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: